secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-08-21T23:59:59+00:00
Accession:  0001104659-25-081480
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 3.03, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin shareholders approve increase in shares from 100M to 5B; Sally Lawlor named new CFO
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized ordinary shares from 100,000,000 to 5,000,000,000 (50x).
- Sally Lawlor appointed CFO effective Aug 18, 2025; base salary €380,000, bonus up to 50%, pension, health insurance.
- Ms. Lawlor is the niece of CEO Dr. Michael Myers; prior roles at Sebela Pharma, Aptiv Plc, and KPMG.
- Shareholders also approved new Compensation Policy and 2025 Equity Incentive Plan.
- Prior CFO Gordon Dunn's last day was Aug 15, 2025; separation agreement pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925081480/0001104659-25-081480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925081480/tm2524078d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-081480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer